The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Results from PARADIGM: aza-ven versus conventional chemo for newly diagnosed fit adults with AML
Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, presents the results of the PARADIGM study (NCT04801797), a Phase II randomized trial comparing azacitidine and venetoclax (aza-ven) to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia (AML). The study met its primary endpoint, with significantly longer event-free survival (EFS) in the aza-ven arm, as well as higher rates of overall response (OR) and composite remission rate (CCR). Additionally, Dr Fathi highlights that treatment with aza-ven was associated with superior tolerability and led to significant improvements in key secondary endpoints. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
